Skip to main content
Top
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

A role of BRCA1 and BRCA2germline mutations in breast cancer susceptibility within Sardinian population

Authors: Grazia Palomba, Angela Loi, Antonella Uras, Patrizia Fancello, Giovanna Piras, Attilio Gabbas, Antonio Cossu, Mario Budroni, Antonio Contu, Francesco Tanda, Antonio Farris, Sandra Orrù, Carlo Floris, Marina Pisano, Mario Lovicu, Maria Cristina Santona, Gennaro Landriscina, Laura Crisponi, Giuseppe Palmieri, Maria Monne

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

In recent years, numerous studies have assessed the prevalence of germline mutations in BRCA1 and BRCA2 genes in various cohorts. We here extensively investigated the prevalence and geographical distribution of BRCA1-2 mutations in the entire genetically-homogeneous Sardinian population. The occurrence of phenotypic characteristics which may be predictive for the presence of BRCA1-2 germline mutations was also evaluated.

Methods

Three hundred and forty-eight breast cancer patients presenting a familial recurrence of invasive breast or ovarian carcinoma with at least two affected family members were screened for BRCA1-2 mutations by DHPLC analysis and DNA sequencing. Association of BRCA1 and BRCA2 mutational status with clinical and pathological parameters was evaluated by Pearson's Chi-Squared test.

Results and Conclusion

Overall, 8 BRCA1 and 5 BRCA2 deleterious mutations were detected in 35/348 (10%) families; majority (23/35;66%) of mutations was found in BRCA2 gene. The geographical distribution of BRCA1-2 mutations was related to three specific large areas of Sardinia, reflecting its ancient history: a) the Northern area, linguistically different from the rest of the island (where a BRCA2 c.8764_8765delAG mutation with founder effect was predominant); b) the Middle area, land of the ancient Sardinian population (where BRCA2 mutations are still more common than BRCA1 mutations); and c) the South-Western area, with many Phoenician and Carthaginian locations (where BRCA1 mutations are prevalent). We also found that phenotypic features such as high tumor grading and lack of expression of estrogen/progesterone receptors together with age at diagnosis and presence of ovarian cancer in the family may be predictive for the presence of BRCA1-2 germline mutations.
Appendix
Available only for authorised users
Literature
1.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.CrossRefPubMed Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.CrossRefPubMed
2.
go back to reference Budroni M, Cesaraccio R, Pirino D, Sechi O, Oggiano M, Piras D, Sechi A, Cossu A, Palmieri G, Tanda F: Cancer incidence in Sassari Province (1998–2002). Cancer Incidence in Five Continents. Edited by: Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P. 2007, IARC Scientific Publications, No. 160, Lyon, IARC, IX: Budroni M, Cesaraccio R, Pirino D, Sechi O, Oggiano M, Piras D, Sechi A, Cossu A, Palmieri G, Tanda F: Cancer incidence in Sassari Province (1998–2002). Cancer Incidence in Five Continents. Edited by: Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P. 2007, IARC Scientific Publications, No. 160, Lyon, IARC, IX:
3.
go back to reference Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R, SEARCH collaborators, Meyer KB, Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D, Evans DG, Peto J, Fletcher O, et al: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007, 447: 1087-1093. 10.1038/nature05887.CrossRefPubMedPubMedCentral Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, Bowman R, SEARCH collaborators, Meyer KB, Haiman CA, Kolonel LK, Henderson BE, Le Marchand L, Brennan P, Sangrajrang S, Gaborieau V, Odefrey F, Shen CY, Wu PE, Wang HC, Eccles D, Evans DG, Peto J, Fletcher O, et al: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007, 447: 1087-1093. 10.1038/nature05887.CrossRefPubMedPubMedCentral
4.
go back to reference Stacey SN, Manolescu A, Sulem P, Rafnar T, Gudmundsson J, Gudjonsson SA, Masson G, Jakobsdottir M, Thorlacius S, Helgason A, Aben KK, Strobbe LJ, Albers-Akkers MT, Swinkels DW, Henderson BE, Kolonel LN, Le Marchand L, Millastre E, Andres R, Godino J, Garcia-Prats MD, Polo E, Tres A, Mouy M, Saemundsdottir J, Backman VM, Gudmundsson L, Kristjansson K, Bergthorsson JT, Kostic J, Frigge ML, Geller F, Gudbjartsson D, Sigurdsson H, Jonsdottir T, Hrafnkelsson J, Johannsson J, Sveinsson T, Myrdal G, Grimsson HN, Jonsson T, von Holst S, Werelius B, Margolin S, Lindblom A, Mayordomo JI, Haiman CA, Kiemeney LA, Johannsson OT, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K: Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 2007, 39: 865-869. 10.1038/ng2064.CrossRefPubMed Stacey SN, Manolescu A, Sulem P, Rafnar T, Gudmundsson J, Gudjonsson SA, Masson G, Jakobsdottir M, Thorlacius S, Helgason A, Aben KK, Strobbe LJ, Albers-Akkers MT, Swinkels DW, Henderson BE, Kolonel LN, Le Marchand L, Millastre E, Andres R, Godino J, Garcia-Prats MD, Polo E, Tres A, Mouy M, Saemundsdottir J, Backman VM, Gudmundsson L, Kristjansson K, Bergthorsson JT, Kostic J, Frigge ML, Geller F, Gudbjartsson D, Sigurdsson H, Jonsdottir T, Hrafnkelsson J, Johannsson J, Sveinsson T, Myrdal G, Grimsson HN, Jonsson T, von Holst S, Werelius B, Margolin S, Lindblom A, Mayordomo JI, Haiman CA, Kiemeney LA, Johannsson OT, Gulcher JR, Thorsteinsdottir U, Kong A, Stefansson K: Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 2007, 39: 865-869. 10.1038/ng2064.CrossRefPubMed
5.
go back to reference Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennet LM, Ding W: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994, 266: 66-71. 10.1126/science.7545954.CrossRefPubMed Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennet LM, Ding W: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994, 266: 66-71. 10.1126/science.7545954.CrossRefPubMed
6.
go back to reference Wooster R, Bignell G, Lancaster J, Swift S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G: Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995, 378: 789-792. 10.1038/378789a0.CrossRefPubMed Wooster R, Bignell G, Lancaster J, Swift S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G: Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995, 378: 789-792. 10.1038/378789a0.CrossRefPubMed
7.
go back to reference Easton D: Breast cancer genes – what are the real risks?. Nat Genet. 1997, 16: 210-211. 10.1038/ng0797-210.CrossRefPubMed Easton D: Breast cancer genes – what are the real risks?. Nat Genet. 1997, 16: 210-211. 10.1038/ng0797-210.CrossRefPubMed
8.
go back to reference Szabo C, Masiello A, Ryan JF, The BIC Consortium, Brody LC: The Breast Cancer Information Core: Database Design, Structure, and Scope. Hum Mut. 2000, 16: 123-131. 10.1002/1098-1004(200008)16:2<123::AID-HUMU4>3.0.CO;2-Y.CrossRefPubMed Szabo C, Masiello A, Ryan JF, The BIC Consortium, Brody LC: The Breast Cancer Information Core: Database Design, Structure, and Scope. Hum Mut. 2000, 16: 123-131. 10.1002/1098-1004(200008)16:2<123::AID-HUMU4>3.0.CO;2-Y.CrossRefPubMed
10.
go back to reference Nedelcu R, Liede A, Aubé J, Finch A, Kwan E, Jack E, NaroD SA, Randall S, Hugel L, Clark K: BRCA mutations in Italian breast/ovarian cancer families. Eur J Hum Genet. 2002, 10: 150-152. 10.1038/sj.ejhg.5200755.CrossRefPubMed Nedelcu R, Liede A, Aubé J, Finch A, Kwan E, Jack E, NaroD SA, Randall S, Hugel L, Clark K: BRCA mutations in Italian breast/ovarian cancer families. Eur J Hum Genet. 2002, 10: 150-152. 10.1038/sj.ejhg.5200755.CrossRefPubMed
11.
go back to reference Pisano M, Cossu A, Persico I, Palmieri G, Angius A, Casu G, Palomba G, Sarobba MG, Rocca PC, Dedola MF, Olmeo N, Pasca A, Budroni M, Marras V, Pisano A, Farris A, Massarelli G, Pirastu M, Tanda F: Identification of a founder BRCA2 mutation in Sardinia. Br J Cancer. 2000, 82: 553-9. 10.1054/bjoc.1999.0963.CrossRefPubMedPubMedCentral Pisano M, Cossu A, Persico I, Palmieri G, Angius A, Casu G, Palomba G, Sarobba MG, Rocca PC, Dedola MF, Olmeo N, Pasca A, Budroni M, Marras V, Pisano A, Farris A, Massarelli G, Pirastu M, Tanda F: Identification of a founder BRCA2 mutation in Sardinia. Br J Cancer. 2000, 82: 553-9. 10.1054/bjoc.1999.0963.CrossRefPubMedPubMedCentral
12.
go back to reference Marroni F, Cipollini G, Peissel B, D'Andrea E, Pensabene M, Radice P, Caligo MA, Presciuttini S, Bevilacqua G: Reconstructing the Genealogy of a BRCA1 Founder Mutation by Phylogenetic Analysis. Ann Hum Genet. 2008, 72: 310-318. 10.1111/j.1469-1809.2007.00420.x.CrossRefPubMed Marroni F, Cipollini G, Peissel B, D'Andrea E, Pensabene M, Radice P, Caligo MA, Presciuttini S, Bevilacqua G: Reconstructing the Genealogy of a BRCA1 Founder Mutation by Phylogenetic Analysis. Ann Hum Genet. 2008, 72: 310-318. 10.1111/j.1469-1809.2007.00420.x.CrossRefPubMed
13.
go back to reference Papi L, Putignano AL, Congregati C, Zanna I, Sera F, Morrone D, Falchetti M, Turco MR, Ottini L, Palli D, Genuardi M: Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy. Breast Cancer Res Treat. 2008, Papi L, Putignano AL, Congregati C, Zanna I, Sera F, Morrone D, Falchetti M, Turco MR, Ottini L, Palli D, Genuardi M: Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy. Breast Cancer Res Treat. 2008,
14.
go back to reference Palmieri G, Palomba G, Cossu A, Pisano M, Dedola MF, Sarobba MG, Farris A, Olmeo N, Contu A, Pasca A, Satta MP, Persico I, Carboni AA, Cossu-Rocca P, Contini M, Mangion J, Stratton MR, Tanda F: BRCA1 and BRCA2 germline mutations in Sardinian breast cancer families and their implications for genetic counseling. Ann Oncol. 2002, 13: 1899-1907. 10.1093/annonc/mdf326.CrossRefPubMed Palmieri G, Palomba G, Cossu A, Pisano M, Dedola MF, Sarobba MG, Farris A, Olmeo N, Contu A, Pasca A, Satta MP, Persico I, Carboni AA, Cossu-Rocca P, Contini M, Mangion J, Stratton MR, Tanda F: BRCA1 and BRCA2 germline mutations in Sardinian breast cancer families and their implications for genetic counseling. Ann Oncol. 2002, 13: 1899-1907. 10.1093/annonc/mdf326.CrossRefPubMed
15.
go back to reference Rosatelli MC, Dozy A, Faà V, Meloni A, Sardu R, Saba L, Kan YW, Cao A: Molecular characterization of beta-thalassemia in the Sardinian population. Am J Hum Genet. 1992, 50: 422-446.PubMedPubMedCentral Rosatelli MC, Dozy A, Faà V, Meloni A, Sardu R, Saba L, Kan YW, Cao A: Molecular characterization of beta-thalassemia in the Sardinian population. Am J Hum Genet. 1992, 50: 422-446.PubMedPubMedCentral
16.
go back to reference Loudianos G, Dessi V, Lovicu M, Angius A, Altuntas B, Giacchino R, Marazzi M, Marcellini M, Sartorelli MR, Sturniolo GC, et al: Mutation analysis in patients of Mediterranean descent with Wilson disease: identification of 19 novel mutations. J Med Genet. 1999, 36: 833-836.PubMedPubMedCentral Loudianos G, Dessi V, Lovicu M, Angius A, Altuntas B, Giacchino R, Marazzi M, Marcellini M, Sartorelli MR, Sturniolo GC, et al: Mutation analysis in patients of Mediterranean descent with Wilson disease: identification of 19 novel mutations. J Med Genet. 1999, 36: 833-836.PubMedPubMedCentral
17.
go back to reference Lampis R, Morelli L, Macis MD, Mulargia A, Loddo M, De Virgiliis S, Marrosu MG, Todd JA, Cucca F: The inter-regional distribution of HLA class II haplotypes indicates the suitability of the Sardinian population for case-control association studies in complex diseases. Hum Mol Genet. 2000, 9: 2959-2965. 10.1093/hmg/9.20.2959.CrossRefPubMed Lampis R, Morelli L, Macis MD, Mulargia A, Loddo M, De Virgiliis S, Marrosu MG, Todd JA, Cucca F: The inter-regional distribution of HLA class II haplotypes indicates the suitability of the Sardinian population for case-control association studies in complex diseases. Hum Mol Genet. 2000, 9: 2959-2965. 10.1093/hmg/9.20.2959.CrossRefPubMed
18.
go back to reference Palomba G, Pisano M, Cossu A, Budroni M, Dedola MF, Farris A, Contu A, Baldinu P, Tanda F, Palmieri G: Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian breast cancer patients through a hospital-based screening. Cancer. 2005, 104: 1172-1179. 10.1002/cncr.21298.CrossRefPubMed Palomba G, Pisano M, Cossu A, Budroni M, Dedola MF, Farris A, Contu A, Baldinu P, Tanda F, Palmieri G: Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian breast cancer patients through a hospital-based screening. Cancer. 2005, 104: 1172-1179. 10.1002/cncr.21298.CrossRefPubMed
19.
go back to reference Monne M, Piras G, Fancello P, Santona MC, Uras A, Landriscina G, Mastio G, Gabbas A: Identification of a founder BRCA2 mutation in Sardinian breast cancer families. Fam Cancer. 2007, 6: 73-79. 10.1007/s10689-006-9107-7.CrossRefPubMed Monne M, Piras G, Fancello P, Santona MC, Uras A, Landriscina G, Mastio G, Gabbas A: Identification of a founder BRCA2 mutation in Sardinian breast cancer families. Fam Cancer. 2007, 6: 73-79. 10.1007/s10689-006-9107-7.CrossRefPubMed
20.
go back to reference Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988, 16: 1215-10.1093/nar/16.3.1215.CrossRefPubMedPubMedCentral Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988, 16: 1215-10.1093/nar/16.3.1215.CrossRefPubMedPubMedCentral
22.
go back to reference den Dunnen JT, Antonarakis SE: Nomenclature for the description of human sequence variations. Hum Genet. 2001, 109: 121-124. 10.1007/s004390100505.CrossRefPubMed den Dunnen JT, Antonarakis SE: Nomenclature for the description of human sequence variations. Hum Genet. 2001, 109: 121-124. 10.1007/s004390100505.CrossRefPubMed
25.
go back to reference Elston CW, Ellis IO, Pathological prognostic factors in breast cancer: The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19: 403-410. 10.1111/j.1365-2559.1991.tb00229.x.CrossRefPubMed Elston CW, Ellis IO, Pathological prognostic factors in breast cancer: The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19: 403-410. 10.1111/j.1365-2559.1991.tb00229.x.CrossRefPubMed
26.
go back to reference Sobin LH, Fleming ID: TNM classification of malignant tumours, 5th edition(1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997, 80: 1803-1804. 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9.CrossRefPubMed Sobin LH, Fleming ID: TNM classification of malignant tumours, 5th edition(1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997, 80: 1803-1804. 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9.CrossRefPubMed
27.
go back to reference Caramelli D, Vernesi C, Sanna S, Sampietro L, Lari M, Castrì L, Vona G, Floris R, Francalacci P, Tykot R, Casoli A, Bertranpetit J, Lalueza-Fox C, Bertorelle G, Barbujani G: Genetic variation in prehistoric Sardinia. Hum Genet. 2007, 122 (3–4): 327-36. 10.1007/s00439-007-0403-6.CrossRefPubMed Caramelli D, Vernesi C, Sanna S, Sampietro L, Lari M, Castrì L, Vona G, Floris R, Francalacci P, Tykot R, Casoli A, Bertranpetit J, Lalueza-Fox C, Bertorelle G, Barbujani G: Genetic variation in prehistoric Sardinia. Hum Genet. 2007, 122 (3–4): 327-36. 10.1007/s00439-007-0403-6.CrossRefPubMed
28.
go back to reference Service S, Deyoung J, Karayiorgou M, Roos JL, Pretorious H, Bedoya G, Ospina J, Ruiz-Linares A, Macedo A, Palha JA, Heutink P, Aulchenko Y, Oostra B, van Duijn C, Jarvelin MR, Varilo T, Peddle L, Rahman P, Piras G, Monne M, Murray S, Galver L, Peltonen L, Sabatti C, Collins A, Freimer N: Magnitude and distribution of linkage disequilibrium in population isolates and implications for genome-wide association studies. Nature Genetics. 2006, 38: 556-560. 10.1038/ng1770.CrossRefPubMed Service S, Deyoung J, Karayiorgou M, Roos JL, Pretorious H, Bedoya G, Ospina J, Ruiz-Linares A, Macedo A, Palha JA, Heutink P, Aulchenko Y, Oostra B, van Duijn C, Jarvelin MR, Varilo T, Peddle L, Rahman P, Piras G, Monne M, Murray S, Galver L, Peltonen L, Sabatti C, Collins A, Freimer N: Magnitude and distribution of linkage disequilibrium in population isolates and implications for genome-wide association studies. Nature Genetics. 2006, 38: 556-560. 10.1038/ng1770.CrossRefPubMed
29.
go back to reference Cipollini G, Tommasi S, Paradiso A, Aretini P, Bonatti F, Brunetti I, Bruno M, Lombardi G, Schittulli F, Sensi E, Tancredi M, Bevilacqua G, Caligo MA: Genetic alterations in hereditary breast cancer. Ann Oncol. 2004, 15: I7-I13. 10.1093/annonc/mdh651.CrossRefPubMed Cipollini G, Tommasi S, Paradiso A, Aretini P, Bonatti F, Brunetti I, Bruno M, Lombardi G, Schittulli F, Sensi E, Tancredi M, Bevilacqua G, Caligo MA: Genetic alterations in hereditary breast cancer. Ann Oncol. 2004, 15: I7-I13. 10.1093/annonc/mdh651.CrossRefPubMed
30.
go back to reference Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjörd JE: A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996, 13: 117-119. 10.1038/ng0596-117.CrossRefPubMed Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian SV, Tulinius H, Ogmundsdottir HM, Eyfjörd JE: A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 1996, 13: 117-119. 10.1038/ng0596-117.CrossRefPubMed
31.
go back to reference Górski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, Pluzañska A, Bebenek M, Fischer-Maliszewska L, Grzybowska E, Narod SA, Lubiñski J: Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet. 2000, 66: 1963-1968. 10.1086/302922.CrossRefPubMedPubMedCentral Górski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, Pluzañska A, Bebenek M, Fischer-Maliszewska L, Grzybowska E, Narod SA, Lubiñski J: Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet. 2000, 66: 1963-1968. 10.1086/302922.CrossRefPubMedPubMedCentral
32.
go back to reference Verhoog LC, Ouweland van den AM, Berns E, van Veghel-Plandsoen MM, van Staveren IL, Wagner A, Bartels CC, Tilanus-Linthorst MM, Devilee P, Seynaeve C, Halley DJ, Niermeijer MF, Klijn JG, Meijers-Heijboer H: Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. Eur J Cancer. 2001, 37: 2082-2090. 10.1016/S0959-8049(01)00244-1.CrossRefPubMed Verhoog LC, Ouweland van den AM, Berns E, van Veghel-Plandsoen MM, van Staveren IL, Wagner A, Bartels CC, Tilanus-Linthorst MM, Devilee P, Seynaeve C, Halley DJ, Niermeijer MF, Klijn JG, Meijers-Heijboer H: Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families. Eur J Cancer. 2001, 37: 2082-2090. 10.1016/S0959-8049(01)00244-1.CrossRefPubMed
33.
go back to reference Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, Sarantaus L, Kainu T, Syrjäkoski K, Pyrhönen S, Kallioniemi OP, Muhonen T, Luce M, Frank TS, Nevanlinna H: Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet. 1997, 6: 2309-2315. 10.1093/hmg/6.13.2309.CrossRefPubMed Vehmanen P, Friedman LS, Eerola H, McClure M, Ward B, Sarantaus L, Kainu T, Syrjäkoski K, Pyrhönen S, Kallioniemi OP, Muhonen T, Luce M, Frank TS, Nevanlinna H: Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet. 1997, 6: 2309-2315. 10.1093/hmg/6.13.2309.CrossRefPubMed
34.
go back to reference Russo A, Calò V, Valentina Agnese V, Bruno Corsa S: BRCA1 genetic testing in 106 breast and ovarian cancer families from southern Italy (Sicily): a mutation analyses. Breast. 2007, 105: 267-276. Russo A, Calò V, Valentina Agnese V, Bruno Corsa S: BRCA1 genetic testing in 106 breast and ovarian cancer families from southern Italy (Sicily): a mutation analyses. Breast. 2007, 105: 267-276.
35.
go back to reference Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, Cole DE, Provencher D, Ghadirian P, Narod SA: Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet. 1998, 63: 1341-1351. 10.1086/302099.CrossRefPubMedPubMedCentral Tonin PN, Mes-Masson AM, Futreal PA, Morgan K, Mahon M, Foulkes WD, Cole DE, Provencher D, Ghadirian P, Narod SA: Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet. 1998, 63: 1341-1351. 10.1086/302099.CrossRefPubMedPubMedCentral
36.
go back to reference Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999, 91: 904-905. 10.1093/jnci/91.11.943.CrossRef Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999, 91: 904-905. 10.1093/jnci/91.11.943.CrossRef
37.
go back to reference Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, the Breast Cancer Linkage Consortium: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998, 62: 676-689. 10.1086/301749.CrossRefPubMedPubMedCentral Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, the Breast Cancer Linkage Consortium: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998, 62: 676-689. 10.1086/301749.CrossRefPubMedPubMedCentral
38.
go back to reference Malone KE, Daling JR, Neal C, Suter NM, O'Brien C, Cushing-Haugen K, Jonasdottir TJ, Thompson JD, Ostrander EA: Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer. 2000, 88: 1393-1402. 10.1002/(SICI)1097-0142(20000315)88:6<1393::AID-CNCR17>3.0.CO;2-P.CrossRefPubMed Malone KE, Daling JR, Neal C, Suter NM, O'Brien C, Cushing-Haugen K, Jonasdottir TJ, Thompson JD, Ostrander EA: Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer. 2000, 88: 1393-1402. 10.1002/(SICI)1097-0142(20000315)88:6<1393::AID-CNCR17>3.0.CO;2-P.CrossRefPubMed
39.
go back to reference Mikaelsdottir EK, Valgeirsdottir S, Eyfjord JE, Rafnar T: The Icelandic founder mutation BRCA2 999del5: analysis of expression. Breast Cancer Res. 2004, 6: R284-290. 10.1186/bcr785.CrossRefPubMedPubMedCentral Mikaelsdottir EK, Valgeirsdottir S, Eyfjord JE, Rafnar T: The Icelandic founder mutation BRCA2 999del5: analysis of expression. Breast Cancer Res. 2004, 6: R284-290. 10.1186/bcr785.CrossRefPubMedPubMedCentral
40.
go back to reference Liede A, Karlan BY, Narod SA: Cancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2: A Review of the Literature. Journal of Clinical Oncology. 2004, 22: 735-742. 10.1200/JCO.2004.05.055.CrossRefPubMed Liede A, Karlan BY, Narod SA: Cancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2: A Review of the Literature. Journal of Clinical Oncology. 2004, 22: 735-742. 10.1200/JCO.2004.05.055.CrossRefPubMed
41.
go back to reference Rennert G, Bisland-Naggan S, Barnett-Griness O, Naomi Bar-Joseph N, Zhang S, Hedy S, Rennert HS, Narod SA: Clinical Outcomes of Breast Cancer in Carriers of BRCA1 and BRCA2 Mutations. N Engl J Med. 2007, 357: 115-122. 10.1056/NEJMoa070608.CrossRefPubMed Rennert G, Bisland-Naggan S, Barnett-Griness O, Naomi Bar-Joseph N, Zhang S, Hedy S, Rennert HS, Narod SA: Clinical Outcomes of Breast Cancer in Carriers of BRCA1 and BRCA2 Mutations. N Engl J Med. 2007, 357: 115-122. 10.1056/NEJMoa070608.CrossRefPubMed
Metadata
Title
A role of BRCA1 and BRCA2germline mutations in breast cancer susceptibility within Sardinian population
Authors
Grazia Palomba
Angela Loi
Antonella Uras
Patrizia Fancello
Giovanna Piras
Attilio Gabbas
Antonio Cossu
Mario Budroni
Antonio Contu
Francesco Tanda
Antonio Farris
Sandra Orrù
Carlo Floris
Marina Pisano
Mario Lovicu
Maria Cristina Santona
Gennaro Landriscina
Laura Crisponi
Giuseppe Palmieri
Maria Monne
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-245

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine